1. The effect of intravenous immunoglobulin on the course of acute respiratory disease COVID-19. Own observations
- Author
-
M.V. Mokina and O.D. Melnyk
- Subjects
Coronavirus disease 2019 (COVID-19) ,biology ,business.industry ,Acute respiratory disease ,Disease ,Intensive care unit ,law.invention ,law ,Anesthesia ,Concomitant ,Breathing ,biology.protein ,Medicine ,In patient ,Antibody ,business - Abstract
The 2019 coronavirus disease (COVID-19) has infected people in many countries around the world. The discovery of an effective treatment for this disease, especially in severe cases, has been the subject of intensive scientific research. Therefore, the aim of this study was to evaluate the effectiveness of intravenous immunoglobulin (IVIG) administration in patients with severe COVID-19 infection. Patients with acute respiratory disease COVID-19 who received intravenous immunoglobulin in the intensive care unit were examined. All patients underwent non-invasive ventilation and all patients had concomitant pathology. Twenty patients participated in the study, 10 patients received an infusion of intravenous immunoglobulin. Patients who received IVIG were on invasive pulmonary ventilation for an average of 7 days, the condition of patients improved by days 2–3. At the time of transfer to adjacent departments (on average, day 14), the dynamics of the disease improved. Respiration rate was 23 per 1 min. SpO2 without O2 was 92 %. All patients presented with lymphopenia and increased transaminases level, the values of which normalized by days 2–3. When ultrasound examination of the lungs, there were no pulmonary consolidations in patients. Mortality in the group of patients who received IVIG was lower compared to patients who did not receive IVIG.
- Published
- 2022
- Full Text
- View/download PDF